EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Placental Growth Factor Led Management of the Small for Gestational Age Fetus: Randomised Controlled Feasibility Study

Siân Bullough iD, Michelle Dower, Richard Jackson, Alexander E P Heazell iD, Kerry Woolfall, Lazaros Andronis, Louise Kenny, Zarko Alfirevic, Andrew Sharp iD, PLANES study group

BJOG: An International Journal of Obstetrics & Gynaecology · 2026

DOI: 10.1111/1471-0528.70106 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2026. Verfasst von Siân Bullough und 9 weiteren Autor:innen. Beteiligte Einrichtung: Harris Research Centre, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Placenta Growth Factor, Infant, Small for Gestational Age, Fetal Growth Retardation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To determine the feasibility of a trial investigating the optimal timing for the birth of women with a suspected late preterm and term SGA baby using either angiogenic biomarker‐led care or standard care.

Design

A mixed methods study including a randomised feasibility trial, interviews, questionnaires and economic analysis.

Setting

Two tertiary maternity hospitals in the UK. Population Women with suspected SGA pregnancies between 32 +0 weeks gestation and 37 +6 weeks gestation.

Methods

Women were randomised in a 3:1 ratio to biomarker‐led care versus standard care. Biomarker tests were either revealed, with birth delayed until 40 weeks if normal (sFlt‐1/PlGF < 38 pg/mL) and considered from 37 weeks if abnormal (sFlt‐1/PlGF ≥ 38 pg/mL), or concealed alongside standard care. Main Outcome Measures Primary outcome was the feasibility of the study measured through the recruitment rate and adherence. Secondary outcomes were the qualitative, proof‐of‐concept and economic analyses.

Results

Out of 128 women invited to participate 78 women were recruited giving a recruitment rate of 60.1% (95% confidence interval 52%–69%). Sixty‐seven of the 78 women consented to randomisation. Sixteen parents and 12 clinicians were interviewed. Fourty parents completed a questionnaire. Participants, partners and clinicians viewed the study as acceptable but experienced challenges in participation and delivering the study. There were no significant adverse events or differences in neonatal outcomes. Collection of health economics data was feasible.

Conclusions

The clinical, qualitative and economic results support the acceptability of utilising sFlt ‐1/ PlGF to refine SGA management after 32 +0 weeks but the feasibility is less certain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Placenta Growth FactorInfant, Small for Gestational AgeFetal Growth RetardationHumansFemalePregnancyFeasibility StudiesAdultInfant, NewbornBiomarkersGestational AgeVascular Endothelial Growth Factor Receptor-1United Kingdom

Stichwörter der Autor:innen

FGRPlGFSGAangiogenicbiomarkerfeasibilitylate growth restrictionmanagementrandomisedsFlt‐1

Substanzen

Placenta Growth FactorBiomarkersVascular Endothelial Growth Factor Receptor-1PGF protein, human

Autor:innen und Institutionen

  • Harris Research Centre, University of Liverpool, Liverpool, UK.
  • Liverpool Women's Hospital, Liverpool, UK.
  • Department of Health Data Science in the Institute of Public Health Policy and Systems, University of Liverpool, Liverpool, UK.
  • Maternal and Fetal Health Research Centre, University of Manchester, Manchester, UK.
  • Department of Obstetrics, Saint Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
  • Department of Public Health Policy and Systems, University of Liverpool, Liverpool, UK.

ORCID-Profile: Siân Bullough, Alexander E P Heazell, Andrew Sharp

Zitieren

APA

Bullough, S., Dower, M., Jackson, R., Heazell, A. E. P., Woolfall, K., Andronis, L., Kenny, L., Alfirevic, Z., Sharp, A., & PLANES study group (2026). Placental Growth Factor Led Management of the Small for Gestational Age Fetus: Randomised Controlled Feasibility Study. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.70106

Vancouver

Bullough S, Dower M, Jackson R, Heazell AEP, Woolfall K, Andronis L, et al. Placental Growth Factor Led Management of the Small for Gestational Age Fetus: Randomised Controlled Feasibility Study. BJOG: An International Journal of Obstetrics & Gynaecology. 2026. doi:10.1111/1471-0528.70106

BibTeX
@article{Bullough2026,
  author = {Bullough, Siân and Dower, Michelle and Jackson, Richard and Heazell, Alexander E P and Woolfall, Kerry and Andronis, Lazaros and Kenny, Louise and Alfirevic, Zarko and Sharp, Andrew and PLANES study group, PLANES study group},
  title = {Placental Growth Factor Led Management of the Small for Gestational Age Fetus: Randomised Controlled Feasibility Study},
  journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
  year = {2026},
  doi = {10.1111/1471-0528.70106}
}
Kostenlos starten →